Date: 2012-09-04
Type of information: Fundraising
Company: Theravectys (France)
Investors: private investors including
Guy Paillaud former executive manager of Promodes
John Pieters, former CEO of Amgen France
some of the company's historical investors
and 10 new private investors, which include the Tethys fund (Bettenfourt family), Philippe Oddo and Richard Hennessy.
Amount: € 7.48 million
Funding type: fundraising
Planned used: These funds, raised exclusively from private investors, will enable Theravectys to pursue the development of a new generation of vaccines, with an anti-HIV therapeutic vaccine as its first priority. In particular, they will enable the company to fund: - Phase I/II of the clinical trial of its anti-HIV vaccine candidate; - The development of new vaccine candidates based on lentiviral vector technology and concerning other indications; - The planning of new laboratories that are larger and can better accommodate the company’s development
Others: Theravectys, a french biotechnology company that is developing a new generation of vaccines based on lentiviral vector technology, has announced that it has secured €7.48 million as of the end of H1 2012.
Theravectys has developed a new generation of vaccines based on lentiviral vector technology. Built on the result of fundamental research conducted at the Pasteur Institute, this breakthrough technology is expected to enable preventing or effectively treating many diseases in which the induction of effective cellular immune response is required: viral diseases (HIV), bacterial or parasitic diseases, cancers... Since its creation, Theravectys has been working on the development of a therapeutic vaccine against HIV. This vaccine, for which the Phase I/II clinical trial is set to begin in the second half of 2012, should allow HIV-positive patients under combination therapies to discontinue and perhaps even permanently stop taking any antiretroviral treatment once vaccinated.
Therapeutic area: Infectious diseases
